The stock of Novocure Ltd (NASDAQ:NVCR) is a huge mover today! About 154,544 shares traded hands. Novocure Ltd (NASDAQ:NVCR) has declined 36.35% since April 18, 2016 and is downtrending. It has underperformed by 40.78% the S&P500.
The move comes after 6 months positive chart setup for the $848.68 million company. It was reported on Nov, 18 by Barchart.com. We have $12.78 PT which if reached, will make NASDAQ:NVCR worth $271.58 million more.
Novocure Ltd (NASDAQ:NVCR) Ratings Coverage
Out of 5 analysts covering NovoCure (NASDAQ:NVCR), 3 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 60% are positive. NovoCure has been the topic of 6 analyst reports since October 27, 2015 according to StockzIntelligence Inc. The stock has “Market Outperform” rating given by JMP Securities on Tuesday, October 27. The rating was maintained by Wedbush with “Outperform” on Friday, July 29. On Tuesday, October 27 the stock rating was initiated by JP Morgan with “Overweight”. The rating was initiated by Wedbush on Tuesday, October 27 with “Outperform”. Deutsche Bank initiated it with “Hold” rating and $28 target price in Wednesday, December 2 report. The stock of Novocure Ltd (NASDAQ:NVCR) earned “Underweight” rating by Barclays Capital on Tuesday, January 19.
According to Zacks Investment Research, “NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.”
More notable recent Novocure Ltd (NASDAQ:NVCR) news were published by: Fool.com which released: “NovoCure Ltd. Fell 29.7% in October — but Why?” on November 10, 2016, also Marketwatch.com with their article: “Novocure Ltd. NASDAQ: NVCR” published on September 02, 2015, Fool.com published: “Why Novocure Ltd Is Plunging Today” on July 28, 2016. More interesting news about Novocure Ltd (NASDAQ:NVCR) were released by: Quotes.Wsj.com and their article: “Novocure Ltd. NVCR (US: Nasdaq)” published on September 02, 2015 as well as Marketwatch.com‘s news article titled: “NovoCure falls below reduced IPO price in market debut” with publication date: October 02, 2015.
NVCR Company Profile
NovoCure Limited, incorporated on February 11, 2000, is a commercial-stage oncology company. The Firm is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death. A TTFields delivery system includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories. The electric fields are delivered through the non-invasive, insulated transducer arrays that are placed directly on the skin in the region surrounding the tumor. The therapy is designed to be delivered throughout the day and night.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.